Remove 2030 Remove Pharmaceuticals Remove Regulations
article thumbnail

The Benefits of Integrated CDMO Services: Streamlining Drug Development and Manufacturing

Drug Patent Watch

The pharmaceutical industry has undergone significant changes over the past decade, with a growing trend towards outsourcing key aspects of research, development, and manufacturing to third-party vendors. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48

article thumbnail

Boosters and Biologics: Is Space-Based Biomanufacturing Real?

LifeSciVC

1,2,3 Among a long list of innovations, the lowest hanging fruit for commercialization is the use of microgravity-based crystallization to enhance high-value pharmaceuticals. Demand exceeds supply, and there is little hope in clearing the queue many ongoing studies wont even finish prior to the ISSs 2030 retirement.

Science 96
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pharma Contract Sales Outlook 2025–2030: Multilingual Teams Drive Global Expansion

The Pharma Data

Global Pharmaceutical Contract Sales Outsourcing Market to Reach $24.8 Billion by 2030: Strategic Insights, Regional Trends, and Technological Shifts Reshaping the Landscape The global pharmaceutical contract sales outsourcing (CSO) market is entering a transformative phase, with its value expected to grow from $17.3

article thumbnail

Best-in-Class Solutions Accelerate Development of GLP-1 Therapeutics

PPD

Medical researchers and practitioners see in their own patients how these ailments interconnect and overlap, as do the pharmaceutical and biotech companies working to develop GLP-1 therapeutics. However, it is representative of the average across most of todays trials, where only 2030% of participants are women.

article thumbnail

Shaping the Future: Eli Lilly's Role in the Weight Management Revolution

DrugBank

billion in 2022 and is projected to grow at a compound annual growth rate of 9.94% from 2023 to 2030. Eli Lilly's Triumph: Pioneering Solutions in Weight Management Eli Lilly's remarkable achievement with its drug Mounjaro (tirzepatide) in the fourth quarter of 2023 has sent ripples of excitement through the pharmaceutical industry.

article thumbnail

The Race for Ozempic Alternatives: Unlocking the Future of Weight Loss Medication

DrugBank

Pharmaceutical researchers, in particular, have a keen interest in understanding the unfolding dynamics of this market. adults using obesity medications by 2030, further underlining the growing significance of this sector. Let’s delve into what lies ahead in the coming year.

article thumbnail

Article EMA Thank You British regulators tease new device regulations in informative live session

Agency IQ

British regulators tease new device regulations in informative live session This week, the British regulator MHRA offered a new peek into its planned medical device regulations. BY COREY JASEPH, MS, RAC | MAR 5, 2024 11:10 PM CST Quick background on medical device regulation in the U.K. post-market regulation here.]